Traveka Wealth LLC Has $251,000 Stock Position in Danaher Co. (NYSE:DHR)

Traveka Wealth LLC reduced its stake in shares of Danaher Co. (NYSE:DHR) by 14.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,091 shares of the conglomerate’s stock after selling 185 shares during the quarter. Traveka Wealth LLC’s holdings in Danaher were worth $251,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the stock. Courier Capital LLC grew its position in Danaher by 29.5% during the fourth quarter. Courier Capital LLC now owns 2,106 shares of the conglomerate’s stock worth $483,000 after buying an additional 480 shares in the last quarter. Parisi Gray Wealth Management grew its holdings in shares of Danaher by 0.5% during the 4th quarter. Parisi Gray Wealth Management now owns 15,749 shares of the conglomerate’s stock worth $3,615,000 after purchasing an additional 73 shares in the last quarter. Pallas Capital Advisors LLC increased its position in shares of Danaher by 132.2% during the fourth quarter. Pallas Capital Advisors LLC now owns 19,278 shares of the conglomerate’s stock valued at $4,425,000 after purchasing an additional 10,976 shares during the period. Miracle Mile Advisors LLC raised its stake in shares of Danaher by 778.9% in the fourth quarter. Miracle Mile Advisors LLC now owns 9,808 shares of the conglomerate’s stock valued at $2,252,000 after purchasing an additional 8,692 shares in the last quarter. Finally, Sunflower Bank N.A. lifted its position in Danaher by 9.5% in the fourth quarter. Sunflower Bank N.A. now owns 1,530 shares of the conglomerate’s stock worth $351,000 after purchasing an additional 133 shares during the period. 79.05% of the stock is owned by institutional investors.

Danaher Stock Performance

DHR stock opened at $239.83 on Tuesday. The company has a 50 day moving average price of $235.52 and a 200 day moving average price of $253.65. Danaher Co. has a fifty-two week low of $222.53 and a fifty-two week high of $281.70. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The stock has a market capitalization of $173.22 billion, a PE ratio of 45.77, a price-to-earnings-growth ratio of 4.32 and a beta of 0.83.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm’s quarterly revenue was up 3.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.02 earnings per share. Analysts forecast that Danaher Co. will post 7.5 EPS for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. The ex-dividend date is Friday, December 27th. Danaher’s dividend payout ratio (DPR) is 20.61%.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on DHR shares. Bank of America upgraded shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective for the company in a research note on Friday, December 13th. Wolfe Research upgraded shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target for the company in a research note on Thursday, October 31st. Royal Bank of Canada lowered their price objective on Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Robert W. Baird cut their target price on Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Finally, Guggenheim initiated coverage on Danaher in a research report on Thursday, December 19th. They issued a “buy” rating and a $275.00 price target on the stock. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $286.80.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.